Postoperative Instillation of Low-Dose Mitomycin C in the Treatment of Primary Pterygium

Hayasaka, Seiji; Noda, Sachiko; Yamamoto, Yukari; Setogawa, Tomoichi

doi:10.1016/0002-9394(88)90706-4

Cited by 173 publications

(69 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Exact mechanism of its antifibroblastic activity is still elusive but possibly it inhibits fibroblast activity and suppresses fibrosis and scar formation by apoptosis. [3] Use of Mitomycin-C has been well documented in variFull text online at http://www.jiaps.com ous ophthalmologic procedures [4][5][6] and laryngeal/tracheal conditions [3] where it has been shown that Mitomycin-C inhibited fibroblast proliferation during the postoperative phase without damaging the mucosal and epithelial growth.…”

Section: Introductionmentioning

confidence: 99%

Topical application of mitomycin-C in corrosive esophageal strictures

Kumar

Bhatnagar

2005

J Indian Assoc Pediatr Surg

View full text Add to dashboard Cite

ABSTRACT ABSTRACT ABSTRACTIntroduction: Corrosive ingestion is the major cause of esophageal stricture in our country. Mitomycin-C, an anthracycline derived from Streptomyces caespitosus, has both antineoplastic and antiproliferative properties. Use of mitomycin-C have been well documented in various ophthalmologic procedures and laryngo-tracheal conditions where it has been shown that mitomycin-C inhibited fibroblast proliferation during the postoperative phase without damaging the mucosal and epithelial growth. This preliminary report documents the use of mitomycin-C in caustic stricture esophagus. Materials and Methods: A prospective study was carried out in ten known patients of caustic esophageal strictures. After taking informed consent patients were subjected to antegrade or retrograde esophageal dilatation under general anesthesia and mitomycin-C was applied topically by a 10 mm cottonoid sponge soaked in mitomycin-C solution (0.4 mg/ml) for 5 minutes at the stricture site. The procedure was repeated at 4 weekly intervals thereafter and need for further dilatation was assessed. Outcomes in terms of symptomatic relief and radiological evaluation were assessed after therapy and results were analyzed for effectiveness of mitomycin-C and compared with retrospective results of previous cases of corrosive ingestion managed at the same institution. Results: Total number of dilatations required were 34 (mean -3.4) Two patients required single dilatation while two required six sessions. Symptomatic as well as radiological improvement was present in nine patients. Conclusions: Use of mitomycin-C seems to improve the outcome in patients of corrosive esophageal strictures. Patients who have undergone esophageal replacement also seem to benefit from mitomycin-C.

show abstract

Section: Introductionmentioning

confidence: 99%

Topical application of mitomycin-C in corrosive esophageal strictures

Kumar

Bhatnagar

2005

J Indian Assoc Pediatr Surg

View full text Add to dashboard Cite

show abstract

“…However, postoperative complications were reported even when a low dosage of mitomycin was applied (Rubinfeld et al 1992;Gunalp & Simsek 1996). The major reasons for complications were related to uncontrolled and prolonged use of the drug by the patients (Hayasaka et al 1989). Unlike postoperative mitomycin therapy, intraoperative use of mitomycin provides the surgeon direct control over the method (e.g., concentration, duration, location) of mitomycin appli- cation.…”

mentioning

confidence: 99%

Intraoperative application versus postoperative mitomycin C eye drops in pterygium surgery

Oğuz¹,

Başar

Gürler³

1999

Acta Ophthalmologica Scandinavica

View full text Add to dashboard Cite

ABSTRACT.Purpose: Postoperative recurrence of pterygium occurs in many patients. Intraoperative and postoperative mitomycin therapy are two adjuvant treatment methods shown to lessen the high pterygium recurrence rate seen with simple excision alone. The authors designed a prospective, randomized study to explore the recurrence rate of pterygium after a single dosage of mitomycin C at the completion of pterygium excision, comparing it to postoperative mitomycin C therapy. Methods: Thirty-six patients with 40 primary and recurrent pterygia were randomized to 1 of 2 treatment groups: intraoperative mitomycin 0.2 mg/ml for 5 minutes (group 1) and postoperative mitomycin 0.2 mg/ml four times a day for 7 days (group 2). The mean follow-up time was 15 months (range, 6 to 24 months).

show abstract

“…Employing postoperative mitomycin-C drops or intraoperative single dose mitomycin-C was reported to reduce the recurrence rate after pterygium excision as low as 0% to 12% (5,21,24). Anduze, in a ten-year study, reported mild and easily resolved adverse effects with the single intraoperative application of 0.1 cc of 0.4 mg/ml of mitomycin-C into the subconjunctival space (4).…”

Section: Discussionmentioning

confidence: 99%

Conjunctival Z-Plasty for Pterygium: Comparison With Conjunctival Autografting

Özdemir

2008

ELECTRON J GEN MED

View full text Add to dashboard Cite

Postoperative Instillation of Low-Dose Mitomycin C in the Treatment of Primary Pterygium

Cited by 173 publications

References 3 publications

Topical application of mitomycin-C in corrosive esophageal strictures

Topical application of mitomycin-C in corrosive esophageal strictures

Intraoperative application versus postoperative mitomycin C eye drops in pterygium surgery

Conjunctival Z-Plasty for Pterygium: Comparison With Conjunctival Autografting

Contact Info

Product

Resources

About